Summit Therapeutics Inc. - 8-K Filing
Summit Therapeutics reports Q2 financial results and clinical updates on ivonescimab including updated OS data for HARMONi trial (Items: 2.02 as if fully set forth herein, 7.01 as if fully set forth herein)
Tickers: $SMMT